Related Experiment Video

Updated: Aug 20, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Role of angiotensin receptor blockers in patients with left ventricular dysfunction: lessons from CHARM and VALIANT

A A Voors, D J van Veldhuisen

    International Journal of Cardiology
    |November 25, 2004
    PubMed

    Insights

    Angiotensin receptor blockers (ARBs) offer alternatives for heart failure patients unable to use ACE-inhibitors. ARBs show benefits post-myocardial infarction and reduce heart failure hospitalizations.

    Area of Science:

    • Cardiology
    • Pharmacology

    Background:

    • The VALIANT and CHARM trials have redefined the role of angiotensin receptor blockers (ARBs) in managing left ventricular dysfunction.
    • CHARM demonstrated candesartan as a viable option for chronic heart failure patients intolerant to ACE-inhibitors.

    Discussion:

    • VALIANT established valsartan's non-inferiority to captopril in acute myocardial infarction patients.
    • While add-on therapy with ARBs and ACE-inhibitors shows modest effects, a consistent reduction in heart failure hospitalizations is observed.

    Key Insights:

    • ARBs provide crucial therapeutic alternatives for specific patient subgroups with heart failure.
    • Evidence supports ARBs in post-MI care and as a strategy to decrease heart failure-related hospitalizations.

    Outlook:

    • Further research may elucidate optimal ARB use in combination therapies.
    • Continued evaluation of ARBs in diverse cardiovascular patient populations is warranted.

    More Related Videos

    Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

    Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

    Published on: February 13, 2021

    Related Concept Videos

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Aortic Regurgitation III: Medical Management01:25

    Aortic Regurgitation III: Medical Management

    Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

    Antihypertensive Drugs: Angiotensin II Receptor Blockers

    In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...